New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareARA-290 vs Thymosin Beta-4

ARA-290 vs Thymosin Beta-4

Side-by-side comparison of key properties, dosing, and research.

Immune SupportRecovery & Repair
ARA-290
Recovery & RepairAnti-Aging & Longevity
Thymosin Beta-4
Summary
ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
Thymosin Beta-4 is an endogenous 43-amino acid peptide that is the primary intracellular actin sequestering peptide. It promotes tissue repair, reduces inflammation, regenerates hair follicles, and protects cardiac tissue. Closely related to TB-500 (the active fragment), it is used for systemic tissue recovery and anti-aging.
Half-Life
~2–4 hours (SC administration)
Not well characterized; likely similar to TB-500 (~1–2 hours)
Admin Route
SubQ
SubQ, IM
Research
Typical Dose
4 mg (fixed dose)
5–10 mg
Frequency
Once daily
2x per week (loading), then 1x per week (maintenance)
Key Benefits
  • Reduces neuropathic pain from small fiber neuropathy
  • Anti-inflammatory without immune suppression
  • Tissue protection after ischemia/reperfusion injury
  • Promotes nerve fiber regeneration
  • Improves symptoms of sarcoidosis-associated neuropathy
  • May reduce insulin resistance and improve metabolic health
  • Shown to improve autonomic neuropathy symptoms
  • Systemic tissue repair and regeneration
  • Promotes cardiac recovery after myocardial infarction
  • Hair follicle regeneration and anti-hair-loss
  • Anti-inflammatory (systemic)
  • Wound healing acceleration
  • Neuroprotection after brain injury
  • Protects against ischemia-reperfusion injury
  • Anti-aging at cellular level
  • Synergizes powerfully with BPC-157
Side Effects
  • Injection site reactions
  • Mild fatigue at initiation
  • Transient warm sensation post-injection
  • Rare: mild headache
  • Generally very well tolerated
  • Injection site reactions
  • Mild fatigue at initiation (repair signaling)
  • Rare: mild inflammatory response
  • +1 more
Stacks With